Conference Track

Lung Cancer

Source: CCO Independent Conference Coverage of the 2008 American Society of Clinical Oncology Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Phase III FLEX Trial Results: Cetuximab Added to Cisplatin/Vinorelbine Improves Survival in Patients With EGFR-Positive Advanced Non-Small-Cell Lung Cancer
In SWOG Phase III Trial, Irinotecan/Cisplatin Fails to Demonstrate Survival Advantage Over Etoposide/Cisplatin in Extensive SCLC
Topotecan/Cisplatin Noninferior to Etoposide/Cisplatin in Patients With Extensive Disease Small-Cell Lung Cancer
Docetaxel/Cisplatin Plus Concurrent Radiotherapy Safe and Effective in Treatment-Naive Locally Advanced NSCLC
Biomarkers of the Insulin-Like Growth Factor-IR Pathway Useful in Monitoring Anti–IGF-IR Therapeutic Response
Pemetrexed Maintenance Therapy After Platinum Induction Prolongs PFS for Patients With NSCLC
Sequential Gefitinib Therapy After Platinum Doublet Chemotherapy Shows Promise for Improving OS for NSCLC Patients With Adenocarcinoma
TLR Agonist PF-676 Fails to Show Benefit When Used With Paclitaxel/Carboplatin for First-Line Treatment of Advanced NSCLC
TLR Agonist PF-676 Shows No Benefit Combined With Gemcitabine/Cisplatin for First-Line Treatment of Advanced NSCLC

Expert Analysis

Lung Cancer

Program Director: Ramaswamy Govindan, MD

Faculty:

David R. Gandara, MD
Thomas J. Lynch, MD
Alan B. Sandler, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize recent data on the use of antibodies to epidermal growth factor receptor in treatment of non-small-cell lung cancer
Discuss the current status of the use of biomarkers in patient selection for treatment with epidermal growth factor receptor–targeting agents in non-small-cell lung cancer
Summarize results of reported investigation of insulin-like growth factor type I receptor antibodies in initial therapy for patients with non-small-cell lung cancer
Discuss reported data on maintenance therapy in non-small-cell lung cancer and their clinical implications
Review recent data evaluating the efficacy of topoisomerase inhibitors in the treatment of patients with small-cell lung cancer

CME CREDIT INFORMATION

Release Date: 08/13/08

Expiration Date: 08/12/09

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.1 Nursing CE credits

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.